Abstract-Preeclampsia is a unique multiple system disorder that affects 5% to 8% of pregnancies. Exosomes, membraneencapsulated vesicles that are released into the extracellular environment by many cell types, can carry signals to the recipient cells to affect inflammation, apoptosis, and angiogenesis. We hypothesize that exosomes from women with preeclampsia complications impair vascular development by delivering antiangiogenic factors to endothelial cells. In the current study, plasma samples from gestational age-matched preeclampsia and normal pregnancies were used to isolate circulating exosomes by commercial kits. Next, application of transwell and matrigel tube formation assays showed that exosomes from preeclampsia patients impaired angiogenesis of human umbilical vein endothelial cells. We found that exosomes from preeclampsia expressed abundant sFlt-1 (soluble fms-like tyrosine kinase-1) and sEng (soluble endoglin). Considering the possibility that extracellular sFlt and sEng were horizontally transferred to human umbilical vein endothelial cells, we successfully collected exosomes containing high levels of sFlt-1 and sEng by overexpressing them in human embryonic kidney 293 cells. Furthermore, we demonstrated that these exosomes can attenuate the proliferation, migration, and tube formation of human umbilical vein endothelial cells in vitro. In a mouse model, exosomes from preeclampsia patients caused vascular dysfunction directly resulted in adverse preeclampsia-like birth outcomes. Thus, we proposed that exosomes mediated efficient transfer of sFlt-1 and sEng to endothelial cells to damage vascular functions and induce complications in preeclampsia patients. (Hypertension. 2018;72:1381-1390.
P reeclampsia is a devastating hypertensive complication that occurs after the 20th week of gestation, characterized by new-onset hypertension. 1 This gestation-specific syndrome is a serious pregnancy complication that globally affects 5% to 8% of all pregnancies and remains the leading cause of fetal and maternal morbidity and mortality worldwide. 2 In women with preeclampsia, a significantly altered angiogenic and hemodynamic profile is exhibited compared with normal pregnancies. Placental antiangiogenic factors, including sFlt-1 (soluble fms-like tyrosine kinase-1) 3 and sEng (soluble endoglin), 4 are upregulated and disrupt the maternal endothelium, leading to clinical complications of preeclampsia.
Exosomes are nano-sized membrane vesicles (30-150 nm) formed by the inward budding of late endosomes that are released into the extracellular environment. 5 Exosomes contain a diverse array of signaling molecules (eg, proteins, mRNAs, and microRNAs) 6 and participate in many physiological processes and disease pathogeneses. They are key mediators of cell paracrine action by transferring genetic materials and proteins to target cells by fusion with the cell membrane, where exosomes can regulate recipient cell functions. 7, 8 For example, platelet-derived exosomes can promote angiogenesis by affecting vascular growth factors. 9 Studies have also implicated exosomes in driving the formation of premetastatic tumors and the spread of numerous pathogens. 10, 11 However, their roles in implantation, placental development, and reproductive physiology are only beginning to be understood and appreciated. 12 Our previous research indicated that exosomal miRNAs may be important for regulating angiogenesis to maintain a normal pregnancy. 13 Recent studies have demonstrated that the concentration of exosomes present in the maternal circulation from preeclampsia pregnancies was significantly greater than that of the control group. 14 In addition, microparticles in preeclampsia December 2018 placental explant culture medium contained increased levels of sFlt-1, which causes endothelial dysfunction and leads to multisystem organ injury. 15 The role of exosomes in the cause and progression of complications of pregnancy remains unclear.
Given these observations, we hypothesize that exosomal contents are altered in preeclampsia pregnancies, and they may contribute to poor perinatal outcomes. Here, we provide new evidence that exosomes from preeclampsia patients (PE-exo) can induce vascular endothelial dysfunction by delivering excess sFlt-1 and sEng to endothelial cells, which likely facilitate adverse reproductive events.
Materials and Methods
The techniques and data that support the results of this study are available from the corresponding author on reasonable request.
Study Population and Sample Collection Protocols
Preeclampsia was defined according to maternal blood pressure ≥140/90 mm Hg at least 2 occasions 4 hours apart with proteinuria ≥1+ by dipstick after 20 weeks of gestation in previously normotensive women. Whole blood was collected from a portion of normal pregnancies (38.1±0.4 weeks, n=10) and preeclampsia patients (36.71±0.7 weeks, n=10) before cesarean section via venipuncture in anticoagulant EDTA-K2 and (ethylenediaminetetraacetic acid-K2) centrifuged at 3000g for 20 minutes, as described previously from 2016 to 2017. 16 The demographic and clinical characteristics of this study were recorded in Table. The blood sample collection was approved by the Scientific and Ethical Committee of Shanghai First Maternity and Infant Hospital affiliated with Tongji University. All the samples were collected with a written informed consent provided by the participants.
Exosome Isolation
The plasma exosomes were collected by the ExoQuick (System Bioscience, Inc, SBI, Mountain View) precipitation method. In brief, plasma samples (1 mL) were mixed with thrombin (100 µL, SBI) at room temperature. Two hundred fifty microliters of ExoQuick Solution was added to the supernatants (1:4). After incubation, residual exosome suspensions were centrifuged at 1500g for 30 minutes. Exosome pellets were suspended in 500 µL of PBS and passed through a 0.22-µm filter.
The cell-derived exosomes were isolated by the ExoQuick-TC kit, following the manufacturer's instructions. In brief, human embryonic kidney 293 (HEK293) cells were starved in medium containing 1% BSA for 48 hours. Fifty milliliters of the medium was centrifuged at 3000g for 15 minutes, then 10 mL of ExoQuick Solution was added into supernatant. After being incubated overnight at 4°C, residual exosome suspensions were centrifuged at 1500g for 30 minutes. Exosome pellets were suspended in 250 µL of PBS.
Transmission Electron Microscopy and Nanoparticle Tracking Analysis
Fifteen microliters of exosomes was applied to a continuous carbon grid and negatively stained with 2% uranyl acetate. The size and morphology of the exosomes were examined using a transmission electron microscope at the Laboratory of Electron Microscopy at an acceleration voltage of 120 kV (Chinese Academy of Sciences). The size distribution of the exosomes was determined using NanoSight NS300 Nanoparticle Tracking Analysis. Samples were diluted with PBS (1:1000) before analysis to obtain a particle distribution of 10 and 100 particles per image (optimal, 50 particles per image) before the analysis with the Nanoparticle Tracking Analysis system.
Exosome Labeling
Exosomes were labeled with the fluorescent dye 1,10-dioctadecyl-3,3,30,30-tetramethylindocarbocyanine perchlorate (Dil, red) by addition to PBS and incubated for 20 minutes according to the manufacturer's protocol. 17 The labeled exosome suspensions were filtered using a 100-kDa molecular weight cutoff hollow fiber membrane to remove the excess dye. Human umbilical vein endothelial cells (HUVECs) were seeded in 6-well plates and incubated with the Dillabeled exosomes (100 μg/mL) or PBS for 24 hours. HUVECs were fixed in 4% paraformaldehyde for 10 minutes, and the labeled cells were prepared for fluorescence microscopy.
ELISAs
ELISAs for human sFlt-1 and sEng and mouse sFlt-1 and sEng (R&D Systems) were performed according to the manufacturer's instructions. In brief, exosome lysate was prepared using radioimmunoprecipitation assay buffer for 30 minutes at 4°C and incubated in a 96-well plate precoated with capture antibodies. Samples of cell medium were diluted 1:4 and added into the plate. Wells were washed 3× and incubated with a secondary antibody conjugated to horseradish peroxidase. Then the substrate solution was added, and the optical density was determined at 450 nm. The protein levels were calculated using a standard curve derived from known concentrations of the respective recombinant proteins.
Western Blot Analysis
Exosomes suspended in PBS were prepared by addition of radioimmunoprecipitation assay buffer. Total protein concentration was measured using the bicinchoninic acid assay (Pierce; Thermo Fisher Scientific, Bonn, Germany). Proteins were separated and transferred to polyvinylidene fluoride membranes by gel electrophoresis and electroblotting, respectively. The blots were incubated with exosomespecific antibodies (CD9, CD63, and CD81, 1:1000; SBI), Flotillin-1 (1:5000; Abcam), sFlt-1 (1:1000; R&D Systems), sEng (1:1000; R&D Systems), Flag (1:1000; Sigma-Aldrich, St. Louis, MO), and GAPDH (1:5000; Abmart, Shanghai, China) antibodies overnight at 4°C. Then the blots were incubated for 1 hour at room temperature with a goat anti-rabbit-horseradish peroxidase antibody (1:5000; CST). The immune-reactive bands were detected with a Chemiluminescence Detection Kit (Millipore, Burlington, MA) and visualized using the FluorChem E imaging instrument (Protein Simple, San Jose, CA).
Cell Culture
HUVECs were isolated from 3 individual donors by a standard collagenase enzyme digestion method and cultured steadily in endothelial cell medium (ScienCell, San Diego, CA) containing 5% fetal bovine serum, 1% penicillin/streptomycin, and 1% endothelial cell growth supplement at 37°C, 5% CO 2 .
HEK293 cells (purchased from ATCC) were cultured in DMEM (Invitrogen) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37°C, 5% CO 2 .
Cell Proliferation, Migration, and Tube Formation Assays
Proliferation, migration, and tube formation abilities were assessed using modified systems as described previously. 18 In brief, 2×10 3 cells per well were plated in 96-well plates, and later, different doses of exosomes were added. Cell numbers were assessed using cell counting kit-8 at 450 nm. For migration, 1×10 4 cells were seeded into the upper chambers, and exosomes (100 µg/mL) were added to the lower chambers. After incubation for 16 hours, fluorescent staining (calcein-acetoxymethylester, calcein-AM) of each chamber was performed. The migrated cells were counted by fluorescence analysis (Nikon, Tokyo, Japan). To quantitate the in vitro angiogenesis ability, plates were coated with Matrigel (BD Bioscience, San Jose, CA) substrate. HUVECs in serum-free endothelial cell medium were added and photographed using an inverted microscope within 6 hours.
Construction of Inducible sFlt-1 and sEng Expression in HEK293 Cells
The human sFlt-1 (ID: NM_001159920.1) and sEng (ID: NM_000118.3) cDNA were cloned into Lenti-X Tetracycline-One (TetOne) System expression vector (Clontech, Mountain View, CA). The recombinant lentivirus Tet-sFlt-1 and Tet-sEng (Hanyin Co, Shanghai, China) were prepared and titered to 10 9 TU/mL (transfection unit). To obtain cell lines overexpressing sFlt-1 or sEng only when doxycycline was present, we infected HEK293 cells with lentiviruses expressing Tet-sFlt-1 or Tet-sEng. One microgram per milliliter puromycin was used to select stable cell lines after 48 hours of infection. The efficiency of overexpression was examined by Western blot analysis.
Animal Study
C57BL/6 male and female mice (6-8 weeks) were purchased from the Jackson Laboratory and housed in a temperature-controlled room (24°C) with a 12:12-hour light/dark cycle with free access to chow and water. This project was performed in accordance with animal protocol procedures approved by the Department of Laboratory Animal Science, Tongji University, and the animals were handled according to the guiding principles published in the National Institutes of Health Guide for the Care of Animals and the Institutional Animal Care and Use Committee.
For a consistent and accurate assessment of the gestational age of mouse embryos, C57BL/6 male and female mice were pair housed for 1 night. The day when a vaginal plug was first noted was embryo 0.5 (E0.5). Pregnant mice (n=18) were equally divided into 3 groups and injected with exosomes from normal pregnant women (N-exo; 100 µg/100 µL), PE-exo (100 µg/100 µL) diluted in sterile normal saline and normal saline (NS; 100 µL) via the tail vein on E5.5, E10.5, and E15.5. Blood pressure was noninvasively measured on E18.5 by determining tail blood volume with a volume pressure recording sensor (CODA System; Kent Scientific, Torrington, CT) averaged over a 10-minute period. Embryos were harvested on E19.5, and tissues were obtained before euthanasia as described elsewhere. 19 Urine samples were collected, and albumin/creatinine ratio was measured using Urinary Albumin and Creatinine Assay kits (Abnova, Taipei City, Taiwan, China) according to the manufacturer's instructions.
Preparation of Fluorescent Exosomes for Administration Into Mice
Plasma exosomes were resuspended in saline to 1 µg/µL and labeled with Dil for 20 minutes in the dark. Labeled exosomes (100 μL) were administered into each mouse via the tail vein on E10.5. After 24 hours, placenta, kidney, and liver tissues were obtained and froze in tinfoil immediately. Eight-micrometer-thick frozen sections were scanned for Dil fluorescence, and nuclei were counterstained using DAPI (4',6-diamidino-2-phenylindole).
Hematoxylin and Eosin, Periodic Acid-Schiff, and Immunohistochemistry
Tissues were fixed with 4% paraformaldehyde for 48 hours and processed by conventional procedures. For paraffin-embedded tissue, sections of 3 to 5 μm in thickness were cut from the paraffin-embedded tissues and mounted on poly-L-lysine-coated slides and deparaffinized in xylene, dehydrated in alcohol, and stained with hematoxylin and eosin or Periodic Acid-Schiff. For immunohistochemistry, tissue sections were stained for CD31, a marker of endothelial cells.
Statistics
All data are expressed as the means±SEM and analyzed using SPSS 23.0 statistical analysis software (SPSS Inc, Chicago, IL). Statistical significance was determined by performing paired Student t test, 1-way ANOVA, and Dunnett post hoc test. A *P <0.05 was considered statistically significant.
Results

Plasma Exosomes Isolation, Characterization, and Concentration
Table showed the clinical characteristics of the study groups. As expected, increased blood pressure and proteinuria were evident in the preeclampsia group (n=10) compared with the normal group (n=10). The characteristics of exosomes isolated and purified using a well-established and validated method 20 were presented in Figure 1 . Exosomes exhibited a typical cup-shaped morphology and a diameter of 30 to 150 nm by electron microscopy ( Figure 1A and 1B) . Furthermore, we selected plasma exosomes (n=5 per group) to assess the presence of the exosomal protein markers CD63, CD81, and CD9 ( Figure 1C ). The characteristics of N-exo and PE-exo pregnancies showed no significant differences. In addition, we found that plasma exosomal protein concentrations from preeclampsia patients were slightly higher than those from normal pregnancies (mg exosomal protein/mL plasma), but the difference was not significant (Figure 1D ; P=0.09).
PE-Exo Impair Vascular Angiogenesis by Transferring sFlt-1 and sEng to Endothelial Cells
Preeclampsia was characterized by vascular endothelial damage resulting in multi-organ dysfunction. Therefore, we chose primary HUVECs to study the effects of PE-exo and N-exo on angiogenesis. Dil-labeled exosomes were incubated with HUVECs for 24 hours, and most of the recipient cells were positive for Dil fluorescence (Figure 2A) . A series of cellular analyses were performed in exosome-treated HUVECs, and Figure 2B showed that both N-exo and PE-exo can facilitate HUVEC proliferation compared with the vehicle control (1% BSA); however, cell migration and tube formation were significantly attenuated by PE-exo compared with N-exo ( Figure 2C) . Although previous preeclamptic studies have examined the concentrations and miRNA contents in exosomes, the proteins and functions of exosomes were largely undefined. Because sFlt-1 and sEng have been implicated in the pathogenesis of preeclampsia, we investigated their concentrations in exosomes by Western blot analysis and found that sEng protein levels were significantly increased in preeclampsia (n=5 per group, Figure 2D ). To improve these findings, we enlarged the sample size and demonstrated that both sFlt-1 and sEng concentrations were remarkably elevated in PE-exo compared with N-exo by ELISAs (n=10 per group, Figure 2E ). In addition, after incubation with PE-exo, sFlt-1 protein levels in HUVEC medium increased as a result of endothelial dysfunction ( Figure 2F ).
Exosomes Contain Larger Amounts of sFlt-1 and sEng and Impair Vascular Endothelial Cell Angiogenesis
We used HEK293 Tet-On-sFlt-1 Flag and Tet-On-sEng Flag cell models to identify that exosomes were potential antiangiogenic factor carriers. In the absence of doxycycline, HEK293 cells did not express any detectable sFlt-1 or sEng protein; after induction with different doses of doxycycline, strong signals for both sFlt-1 Flag and sEng Flag were verified by Western blots ( Figure 3A) . Furthermore, we collected HEK293 cell-derived exosomes, and the characteristics were presented in Figure 3B . No significant differences in shapes and diameters were observed in overexpression of sFlt-1 (OV-sFlt-1), overexpression of sEng (OV-sEng), and control (CTL) cells. After doxycycline treatment, all secreted exosomes displayed increased expression of sFlt-1 or sEng ( Figure 3C ). Most exosomes were accepted by recipient HUVECs, without differences among CTL-derived, OV-sFlt-1-derived, and OV-sEng-293-derived exosomes ( Figure 3D ). Cell counting kit-8 assay showed that CTLexo, OV-sFlt-1-exo, and OV-sEng-exo can simulate HUVEC proliferation compared with the vehicle control (1% BSA); however, cell growth was reduced after treatment with OV-sFlt-1-exo and OV-sEng-exo compared with CTL-exo (100 µg/mL, Figure 3E ). In addition, HUVECs incubated with OV-sFlt-1-exo and OV-sEng-exo showed decreased migration compared with those incubated with CTL-exo by transwell assays (100 µg/mL; Figure 3F ). The results above indicated that exosomes containing increased levels of sFlt-1 and sEng can impair vascular angiogenesis.
PE-Exo Cause a Preeclampsia-Like Phenotype in Pregnant Mice
Pregnant mice were injected with exosomes (N-exo, PE-exo, 100 µg/100 µL) or diluent (saline, NS, 100 µL) on E5.5, E10.5, and E15.5. Dil-labeled exosomes were obviously detected in mouse renal and liver tissues, whereas a small number of fluorescence signals were detected in the placentas ( Figure 4A ). Injection of PE-exo resulted in decreased body weight ( Figure 4B ) and elevated blood pressure on E19.5 compared with those of both N-exo and NS groups ( Figure 4C ). Moreover, mice exposed to PE-exo also developed characteristic hallmarks of preeclampsia because of the elevated sFlt-1 and sEng levels in serum ( Figure 4E ). The decrease in body weight was most likely caused by the smaller size, lower birth weights, and decreased number of surviving embryos per litter ( Figure 4F ). The results above indicated that exposure to PE-exo may result in preeclampsia-like adverse reproductive outcomes through an unknown mechanism. Figure 5A showed the histological examination of the placentas, including the labyrinth and junctional zone, and revealed no significant changes in the labyrinth/junctional zone ratio. Nevertheless, extensive vascular damage, especially decreased diameter of blood vessels within the labyrinth, was observed in PE-exo-treated dams. Because feto-maternal exchange occurred in the villous tree (labyrinth) of the placenta, we analyzed the placental vascularization by staining for CD31. Narrowed blood vesicles, which indicated impaired feto-maternal exchange, 21 were observed in the PE-exo group but not in mice treated with either N-exo or NS ( Figure 5B and 5C ). However, our previous study showed that urinary albumin/creatinine ratio was not elevated in dams ( Figure 4D ). In addition, neither glomerular endotheliosis nor mesangial expansion was present in PE-exo-treated mice by hematoxylin and eosin and Periodic Acid-Schiff staining ( Figure 5D ). (25, 50 , 100 μg/mL), 1% BSA (negative control) or 5% fetal bovine serum (FBS; positive control) for 48 h, HUVEC proliferation was analyzed by cell counting kit-8 assay. C, Cell transwell migration and matrigel tube formation response to exosomes (100 μg/mL) were determined; scale bar: 100 μm (1-way ANOVA, *exosome vs 1% BSA, *P<0.05, **P<0.01, ***P<0.001). All data were means±SEM of 3 pairs of independent experiments. D, Western blot showed protein concentrations of sFlt-1 (soluble fms-like tyrosine kinase-1) and sEng (soluble endoglin; n=5 per group, 1-way ANOVA, *P<0.05). E, ELISAs demonstrated that protein levels of sFlt-1 and sEng were elevated in PE-exo compared with N-exo (n=10 per group, 1-way ANOVA, ***P<0.001). F, After incubation with exosomes, sFlt-1 and sEng concentrations in HUVEC medium were measured by ELISA. (1-way ANOVA, **P<0.01.) . C, ELISA analysis demonstrated sFlt-1 and sEng concentrations were hugely increased in OV-sFlt-1 HEK293 cell-derived exosomes (20-fold, paired Student t test, ***P<0.001), OV-sEng HEK293 cell-derived exosomes (10-fold, paired Student t test, ***P<0.001), respectively. D, HUVECs were incubated with 1,10-dioctadecyl-3,3,30,30-tetramethylindocarbocyanine perchlorate (Dil)-labeled cell-derived exosomes (red) for 24 h before fluorescent and phase-contrast images were captured, scale bar: 50 μm. E, After incubation with exosomes (25, 50, 100 μg/mL), 1% BSA (negative control) or 5% fetal bovine serum (FBS; positive control) for 48 h, HUVEC proliferation was analyzed by cell counting kit-8 assay (1-way ANOVA, *exosome vs 1% BSA, *P<0.05, **P<0.01, #OV-sEng-exo vs CTL-exo, #P<0.05, OV-sFlt-1-exo vs CTL-exo, P=0.107). F, Cell migration response to exosomes (100 μg/mL) was determined by transwell assay, scale bar: 100 μm (1-way ANOVA, **P<0.01). All data were means±SEM of 3 pairs of independent experiments performed. 
PE-Exo Adversely Affect Placental Vascular Histopathology
Discussion
Preeclampsia is a unique multiple system disorder that leads to maternal and fetal morbidity and mortality. The roles of exosomes in pregnancy-related disorders are only beginning to be elucidated. In this study, we provided novel evidence that PE-exo caused vascular endothelial dysfunction by delivering abundant sFlt-1 and sEng to HUVECs compared with N-exo. Importantly, we found that PE-exo was associated with adverse reproductive events in a mouse model, which were likely facilitated by impairing vascular function.
It has been suggested that oxidative and inflammatory stress stimulates the trophoblast to shed larger exosomes than those in normal pregnancy. 22 However, we did not observe significant differences in exosomal size between the physiological and pathological conditions (N-exo, 109.85±41.3 nm versus PE-exo, 107.28±33.9 nm). Exosomes present in blood have been shown to increase in vascular disease states, 23 for example, plasma exosome concentrations were elevated in preeclampsia (normal, 3.88±0.23 versus preeclampsia, 6.14±1.45×10 9 total exosomes/mL). 24 In addition, increased numbers of microvesicles and nano-vesicles were extruded from preeclampsia placentas. 25 Consistent with these findings, our present data showed that plasma exosomal protein concentration in preeclampsia patients was slightly increased as a result of the divergence in exosomal contents under pathological pregnancy.
Exosomes seem to play a pivotal role in pregnancy and may participate in gestational vascular complications. 26 Our previous publication demonstrated that exosomes from maternal circulation can facilitate angiogenesis. 13 In our current study, PE-exo displayed weaker potential to promote HUVEC migration and tube formation compared with N-exo. These results supported and expanded on findings that exosomes from preeclampsia placenta can induce endothelial dysfunction. 27 Thus, we suggested that exosomes contain many proand antiangiogenic components that vary under physiological or pathological environments and are capable of affecting angiogenesis.
Preeclamptic women show impaired vascular development as a consequence of aberrant antiangiogenic factors, including sFlt-1 and sEng. In vitro tubulogenesis studies have shown that sFlt-1 and sEng abrogated the vascular reactivity of HUVECs. 28, 29 In this study, we demonstrated that PE-exo contributed to endothelial dysfunction by transmitting sFlt-1 and sEng to HUVECs. The results were consistent with a previous study conducted by Ermini et al, 30 who found that exosomes-released sEng was increased in preeclampsia maternal circulation. Indeed, after incubation with PE-exo, the concentration of sFlt-1 in HUVEC medium was also elevated, although the level of sEng was not increased. To investigate exosomes carry antiangiogenic factors into HUVECs and induce systemic endothelial dysfunction, we collected exosomes containing abundant sFlt-1 and sEng proteins by establishing Lenti-X Tet-On OV-sFlt-1 and OV-sEng HEK293 cells. Both OV-sFlt-1-exo and OV-sEngexo robustly impaired HUVEC proliferation and migration. Our data in the present study contributes to the growing body of evidence showing that PE-exo can deleteriously affect endothelial cell function by efficiently transporting sFlt-1 and sEng into HUVECs.
In a mouse model, we demonstrated that injection of PE-exo resulted in PE-like adverse reproductive outcomes. 31 The significance of this observation that human exosomes were detected in murine tissues still remains unclear, as exosomes extruded from human placenta localized to mice organs 32 and can traffic from the mice amniotic fluid to the placenta and spread through circulation. 33 Human also can absorb cow's milk exosomes and transport them to peripheral tissues. 34 Exosomes have the potential as mediators of intercellular communication even across species and evade from clearance by the macrophages because of their double-layered membrane and nanoscale size, 35, 36 indicating that exosomes from human blood can cross barriers in murine tissues. Both exosome injection groups showed elevated blood pressure compared with the NS-treated group, as N-exo still contained a small amount of sFlt-1 and sEng. Injection of PE-exo caused a strong increase in blood pressure and preeclampsia markers that were absent in other groups as a result of systematic endothelial damage. In addition, widespread vascular endothelial damage in the placenta is an invariable finding in preeclampsia. 37 We found that the placental vascular networks in PE-exo-treated mice were sparse and that the fetal sinusoids were severely narrowed, indicating an impaired maternal blood supply that led to poor nutrition to the developing fetus. Taken together, these results indicated that the vascular function and feto-maternal exchange were damaged because of the injection of PE-exo, which contributed to maternal hypertension and fetal growth restriction.
In the current study, we reported that exosomes from preeclampsia plasma impaired HUVEC migration and tube formation potentially by carrying high levels of sFlt-1 and sEng into endothelial cells. Moreover, our study demonstrated that PE-exo caused adverse placental angiogenesis in pregnant mice and resulted in a PE-like syndrome. Thus, exosomes from preeclampsia patients could act as carriers for antiangiogenic factors in the circulation, inducing downstream interactions between angiogenic factors and target endothelial cells to cause adverse birth outcomes.
Perspectives
In the current study, we demonstrated that exosomes from preeclampsia women with high levels of sFlt-1 and sEng can impair vascular endothelial functions. We provide evidence that exosomes contain abundant sFlt-1 and sEng that can be delivered to HUVECs and impair cell functions. Our in vivo data indicate that exosomes from preeclampsia can induce a preeclampsia-like phenotype in pregnant mice by adversely affecting angiogenesis. These findings are valuable for understanding the pathogenesis of preeclampsia. Thus, we propose that exosomes can serve as potential antiangiogenic factor carriers to impair vascular biological behaviors. Additional studies are required to lucubrate the mechanisms of exosomesinduced vascular dysfunction in preeclampsia and validate the potential use of specific inhibitors to block relevant pathways to treat preeclampsia. 
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